Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

NCT04501705 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Atypical/malignant Meningioma

Interventions

DRUG: Apatinib Mesylate

Sponsor

Beijing Sanbo Brain Hospital